NCT06189898 (FIRASE) is a clinical trial of Re Staging FDG-PET in Esophagus Cancer, sponsored by Sebastian Zschaeck.

Who is sponsoring NCT06189898?

NCT06189898 is sponsored by Sebastian Zschaeck.

What drugs are being tested in NCT06189898?

Interventions in NCT06189898: Re Staging FDG-PET.

What condition does NCT06189898 study?

NCT06189898 studies Esophagus Cancer.

Is NCT06189898 still recruiting?

NCT06189898 is currently recruiting now. Last updated 5 January 2024.

Last reviewed 2024-01-05 · How we verify

NCT06189898: FIRASE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Functional Imaging to Identify Radiosensitive Esophageal Cancer - a Biomarker Validation Study

Recruiting now Last updated 5 January 2024

What this trial tests

trial testing Re Staging FDG-PET in Esophagus Cancer in 48 participants. Currently enrolling.

Timeline

15 December 2023

Primary endpoint
31 January 2029

31 January 2029

Quick facts

Lead sponsor	Sebastian Zschaeck
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	48
Start date	15 December 2023
Primary completion	31 January 2029
Estimated completion	31 January 2029
Sites	1 location across Germany

Drugs / interventions tested

Re Staging FDG-PET

Conditions studied

Esophagus Cancer — all drugs for Esophagus Cancer →

Sponsor

Sebastian Zschaeck

Who can join

18 and older, any sex, with Esophagus Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This trial on biomarker validation investigates the use of innovative re-staging FDG-PET parameters to detect highly chemoradiation (CRT) sensitive squamous cell carcinomas of the esophagus (SCEC) at the end of preoperative or definitive CRT.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Esophagus Cancer

Currently open trials in the same condition.

NCT07070466 — Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA · Phase 2 · recruiting
NCT07063901 — Multimodal Deep Learning for Predicting Treatment Response to Neoadjuvant Chemoimmunotherapy in Esophageal Cancer · recruiting
NCT06550063 — HER2 Status in Esophagogastric Adenocarcinoma and Its Associations With Patient's Clinicopathological Outcomes · recruiting
NCT06385717 — Multicenter Cohort Study of ESD and Chemo-radiotherapy for High-risk Early-stage Esophageal Cancer · recruiting
NCT06430658 — Neoadjuvant Comprehensive Treatment for Unresectable Esophageal Cancer · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06189898 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sebastian Zschaeck
Last refreshed: 5 January 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06189898.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing